Common Contracts
3 similar Development and License Agreement contracts by Kalobios Pharmaceuticals Inc
EX-10.13 23 d361531dex1013.htm DEVELOPMENT AND LICENSE AGREEMENT CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • May 5th, 2020 • California
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), is made effective as of May 11, 2004 (the “Effective Date”), by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with its registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland and having an office at 605 Third Avenue, 33rd Floor, New York, NY 10158, USA (“LICR”), and KALOBIOS PHARMACEUTICALS, INC., a Delaware corporation (“KaloBios”), having an address at 3427 Hillview Avenue, Palo Alto, CA 94304, USA. KaloBios and LICR may be referred to herein individually as a “Party” and collectively as “Parties.”
CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • August 7th, 2012 • Kalobios Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), is made effective as of May 11, 2004 (the “Effective Date”), by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with its registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland and having an office at 605 Third Avenue, 33rd Floor, New York, NY 10158, USA (“LICR”), and KALOBIOS PHARMACEUTICALS, INC., a Delaware corporation (“KaloBios”), having an address at 3427 Hillview Avenue, Palo Alto, CA 94304, USA. KaloBios and LICR may be referred to herein individually as a “Party” and collectively as “Parties.”
CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • June 12th, 2012 • Kalobios Pharmaceuticals Inc • California
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), is made effective as of May 11, 2004 (the “Effective Date”), by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with its registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland and having an office at 605 Third Avenue, 33rd Floor, New York, NY 10158, USA (“LICR”), and KALOBIOS PHARMACEUTICALS, INC., a Delaware corporation (“KaloBios”), having an address at 3427 Hillview Avenue, Palo Alto, CA 94304, USA. KaloBios and LICR may be referred to herein individually as a “Party” and collectively as “Parties.”
